Experience Dedicated to uro-oncology, especially prostate and bladder cancer, running several trials and initiating treatment modality with wide experience in brachytherapy, hypofractionation, toxicity of radiotherapy and Qol research. Leader role in new research on the treatment of oligometastatic prostate cancer. Work in several teams to develop and improve new treatment modalities/regimen. One of the intiaters of the Prostate Center Zuid West in Rotterdam. Responsible for primary prostate research group. Member of the GEC-ESTRO group. Professional experience More than 15 years’ experience in dedicated uro-oncology. At this moment a senior staff member of the department of Radiation Oncology of the UMCG, responsible for uro-oncologic research activities. 2017-present: Senior stafmember radiation oncology department, UMCG, Groningen 2007-2017: consultant Radiation-oncologist, staff member, Daniel den Hoed oncological centre, Erasmus medical centre, Rotterdam 2002-2007: Radiation-oncologist in training. 2000-2001: House officer internal medicine and occupational health, Groningen. 1997: Training general practitioner, Schalkwijk medisch centrum, Haarlem Other relevant Member of GEC-ESTRO group Responsible for primary prostate research. Member of the international stereotactic research group. Important Grants • PI and initiater of the PERYTON study (Grant KWF 12649): PSMA-PET guided hypofractionated salvage prostate bed radiotherapy of biochemical failure after radical prostatectomy for prostate cancer • PI and initiater of the ADOPT study (Grant KWF 12448): Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy (ADOPT) • PI and intiater of the Probach study: Randomized Phase 3 Study On The Assessment Of Late Toxicity By Comparing IMRT High Dose External Beam Radiotherapy Only With External Beam Radiotherapy Combined With HDR Or PDR Brachytherapy In Patients With Intermediate/high Risk Prostate Cancer. Grant KWF 2012 (367K) • PI of Quality of life study: HDR brachytherapy as monotherapy for low and intermediate risk prostate cancer patients. (Grant Theia stichting, 98k) • PI of phase I/II PROGRESS trial: PROstate high-dose-rate Single fraction brachytherapy monotherapy Study. Efficiency Grant EMC (50k) Collaboration in field • Local PI HYPRO trial: HYpofractionated irradiation for PROstate cancer. • Lid of management and scientific team of prostate centre south west Rotterdam, The Netherlands • Member NVRO: Radiation-oncology Dutch association. • Member of quality board of the NVRO (kwaliteit commissie). • Member KNMG: Royal Dutch society of medicine. • Member LPRU: Landelijk Platform Urologische Tumoren. • Member ESTRO: European association for radiation oncology. • Member ASTRO: American association of radiation oncology. • Member ABS: American Brachytherapy Society. • Member GEC-ESTRO group. • Member DUOS (Dutch Uro-Oncology Study group), research group primary prostate cancer.